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Abstract Differentiation-dependent expression of the Na+/
glucose cotransporter (SGLT1) is accompanied by a large,
cAMP-dependent increase in stability of its mRNA. Stabiliza-
tion is mediated by protein binding to a critical uridine-rich
element (URE) in its 3P untranslated region. In the present study,
we demonstrate that HuR, an RNA binding protein of the
embryonic lethal abnormal vision family, binds the SGLT1 URE.
HuR binding was increased after elevation of intracellular cAMP
levels and was dependent on protein phosphorylation. This
interaction was prevented by a substitution mutation previously
shown to block cAMP-dependent reporter message stabilization.
These results implicate HuR as a key mediator of cAMP-
dependent SGLT1 mRNA stabilization. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
The Na/glucose cotransporter SGLT1 mediates active
high-a⁄nity transport of glucose in kidney and intestinal ep-
ithelial cells driven by Na gradients across the membrane
[1,2]. Owing to its key physiological role in maintaining glu-
cose homeostasis, SGLT1 has been extensively characterized
with respect to its transport mechanism and membrane topol-
ogy [3,4]. It is part of a large transporter superfamily with
over 35 homologous members transporting a variety of sub-
strates in bacteria, yeast and mammalian cells [5]. The human
SGLT1 gene contains 15 exons spanning 72 kb [6] and has
been identi¢ed as the locus of inherited glucose^galactose mal-
absorption [7].
SGLT1 exhibits di¡erentiation-regulated expression in the
LLC-PK1 pig kidney epithelial cell line [8,9]. SGLT1 mRNA
is up-regulated post-transcriptionally in response to levels of
cAMP [10]. Using wild-type and mutant reporter messages
transfected into LLC-PK1 cells, we have obtained direct evi-
dence that a uridine-rich element (URE) in the 3P untranslated
region (UTR) of SGLT1 mediates cAMP-dependent stabiliza-
tion of the message [11,12].
In the present study, we demonstrate that HuR, a ubiqui-
tous RNA binding protein of the embryonic lethal abnormal
vision family [13], forms a speci¢c, cAMP-dependent complex
with the URE sequence in SGLT1 mRNA. Our ¢ndings sug-
gest that HuR plays a critical role in cAMP-dependent up-
regulation of SGLT1 expression.
2. Materials and methods
2.1. Materials
3-Isobutyl-1-methylxanthine (IBMX) and potato acid phosphatase,
type III, were obtained from Sigma (St. Louis, MO, USA). Plasmids
T3 ARE-fos and pTet-Myc-over-HuR were obtained from Dr. Ann-
Bin Shyu, University of Texas Medical School, Houston, TX, USA.
An anti-HuR monoclonal antibody 19F12 was obtained from Dr. H.
Furneaux, University of Connecticut Medical School, Farmington,
CT, USA. An anti-c-myc tag IgG1 monoclonal antibody purchased
from Calbiochem (Ab1, cat # OP10L) recognizes residues 410^419 of
the human c-myc sequence. A monoclonal antibody 4B10 to
hnRNPA1 was obtained from Dr. Gideon Dreyfuss, University of
Pennsylvania School of Medicine, and a monoclonal antibody to
AUF1 (hnRNPD) was provided by Dr. Gary Brewer, UMDNJ-RW
Johnson Medical School, Piscataway, NJ, USA. Monoclonal antibod-
ies AC88 and H9010 to hsp90 were provided by Dr. David Toft,
Mayo Clinic, Rochester, MN, USA, and monoclonal antibodies
N27 and C92F3A5 to hsp70 were obtained from Dr. William Welch,
University of California, San Francisco, CA, USA.
2.2. Cell culture
The porcine renal epithelial cell line LLC-PK1 clone G8 exhibits a
proximal tubule-speci¢c phenotype [14]. Cells were cultured as de-
scribed previously [15]. For experiments, cells were seeded at a density
of 104 cells/cm2 and grown for 4 days to a post-con£uent state, then
the phosphodiesterase inhibitor IBMX was added with medium
change to 1 mM ¢nal concentration to the indicated samples. Unless
otherwise stated, cells were harvested at 96 h after addition of IBMX,
with one medium change after 72 h of treatment.
LLC-TAK-B7, a clonal cell line stably expressing the tetracycline-
regulated transactivator, was isolated from LLC-PK1 clone G8 [11].
Cells were propagated in medium containing 30 ng/ml tetracycline to
suppress expression from the plasmid.
2.3. Assay of RNA/protein complex formation
Radiolabeled RNA probe binding to protein was determined in nu-
clear and cytoplasmic extracts by the UV crosslinking and gel mobility
shift assays we have described previously [11]. The indicated sense
RNA probes were synthesized by in vitro transcription in the presence
of [K-32P]uridine triphosphate (3000 Ci/mmol). Nucleotide numbers
refer to the porcine SGLT1 sequence (accession no. M34044) [16].
Plasmids 122 nt/Bam and 122 nt m2/Bam [11], which contain a
TTCGG substitution at nucleotides 2622^2623, were linearized with
BbsI and transcribed with T3 polymerase to yield wild-type and mutant
120 nucleotide (nt) RNA transcripts respectively, which contain SGLT1
nucleotides 2576^2695. The 47 nt transcript contains nucleotides 2596^
2642 and was transcribed using T7 polymerase from a double-stranded
synthetic oligonucleotide template containing the T7 promoter.
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Gel mobility supershift analysis was carried out as described pre-
viously [17]. Brie£y, cytoplasmic or nuclear lysates were incubated for
15 min with the indicated 32P-labeled RNA probe, unprotected RNA
was digested using ribonuclease T1 and then the indicated monoclonal
antibody, or a non-speci¢c control monoclonal antibody, was diluted
1:10 into the RNA/protein binding mixtures. Incubation was contin-
ued for an additional 30 min in the presence of one unit of RNasin
and complexes were resolved on non-denaturing 6% polyacrylamide
gels.
2.4. Transfection of HuR cDNA
Plasmid pTet-Myc-over-HuR contains full-length human HuR
cDNA fused in frame with an N-terminal myc epitope tag, under
regulation of the tetracycline-regulated promoter (tet-OFF) [18].
LLC-PK1 clone B7, which stably expresses the tetracycline-regulated
transactivator [11], was transiently transfected with pTet-Myc-over-
HuR or the empty vector using the calcium phosphate procedure
and cell culture conditions described previously [11]. Where indicated,
cells were treated with 1 mM IBMX immediately after removal of
DNA.
2.5. Western blot analysis
Cell extracts were prepared at 48 h after transient transfections
described previously [17]. Samples of 15 Wg protein were resolved by
10% acrylamide SDS^PAGE, transferred to nitrocellulose and then
probed with a monoclonal antibody to the c-myc epitope tag at
1 Wg/ml, followed by detection using a horseradish peroxidase-conju-
gated second antibody and the ECL Western blotting kit (Amersham
Pharmacia) according to the manufacturer’s instructions.
3. Results
3.1. HuR binds a stability-regulating domain in SGLT1 mRNA
A 120 nt URE at nucleotides 2576^2695 within the 3P UTR
of SGLT1 mRNA conveys a cis-dominant cAMP-dependent
stabilization to chimeric globin reporter messages [11,12].
HuR has been strongly implicated in mRNA stabilization
in the case of cytokine and early-response gene mRNAs
[18,19] and has also been shown to bind regulatory elements
in other categories of mRNAs [20^26]. Minimal sequence re-
quirements for protein binding to the SGLT1 URE obtained
by mutation and deletion analysis [11] are consistent with
those de¢ned for HuR binding to its target mRNAs [13].
We utilized a gel mobility supershift assay to test whether
endogenous HuR forms a complex with the 120 nt regulatory
element of SGLT1 mRNA. LLC-PK1 cell extracts were incu-
bated with a 32P-labeled 120 nt SGLT1 URE riboprobe. After
complex formation and digestion of unprotected RNA, sam-
ples were then incubated with either a monoclonal antibody to
HuR or a control non-speci¢c monoclonal antibody and re-
solved on non-denaturing gels. Nuclear extracts incubated
with the control, non-speci¢c monoclonal antibody formed
several RNA/protein complexes with this probe whereas one
major complex was observed using cytoplasmic extracts (Fig.
1A). A similar pattern was observed in the absence of anti-
body using the same RNA probe [11]. As reported previously
[11], complex formation was increased in extracts from cells
treated with the phosphodiesterase inhibitor IBMX.
Both nuclear and cytoplasmic extracts incubated with the
anti-HuR monoclonal antibody exhibited a supershift of a
major labeled complex (Fig. 1A). The amount of the super-
shifted complex (indicated by bracket) was increased in ex-
tracts from IBMX-treated cells and was also more abundant
in nuclear extracts compared with cytoplasmic extracts. These
observations indicate that endogenous nuclear and cytoplas-
mic HuR forms a cAMP-dependent complex with the SGLT1
URE.
Mutational analysis of the SGLT1 URE has provided a
tool to examine the linkage between RNA/protein binding
assayed in vitro and stability regulation assayed in vivo.
cAMP-dependent stabilization of a globin reporter message
bearing the SGLT1 URE in its 3P UTR was blocked by a
TTCGG substitution at nucleotides 2622^2623 within an es-
sential pentameric uridine motif [11,12]. This mutation also
prevented cAMP-dependent binding of a 38 kDa protein
[11]. Incubation of either nuclear or cytoplasmic extracts
from IBMX-treated cells with a 32P-labeled mutant transcript,
120 nt m2, which contained this mutant substitution, resulted
in greatly reduced complex formation compared with the
wild-type transcript and no supershift with the anti-HuR anti-
body (Fig. 1A). These ¢ndings indicate that HuR binding is
prevented by a mutation which blocks cAMP-dependent
stability regulation.
The HuR binding site was localized to a 47 nt region (nu-
cleotides 2596^2642) localized within the 120 nt URE se-
quence. Results shown in Fig. 1B demonstrate that cytoplas-
mic complexes with the 47 nt RNA transcript were
supershifted by the anti-HuR monoclonal antibody but not
by the control monoclonal antibody. Furthermore, the super-
shifted complex was increased in cytoplasmic extracts from
cells treated with IBMX. Similar results were obtained using
nuclear extracts (data not shown). The 47 nt transcript was
previously shown by UV crosslinking assay to form a single
cAMP-dependent 50 kDa crosslinked RNA/protein complex
in both nuclear and cytoplasmic extracts [11]. This complex
consisted of a 38 kDa protein, identi¢ed by Northwestern
analysis and by a⁄nity isolation on a biotinylated RNA,
plus a protected RNA fragment [11]. Taken together, these
¢ndings identify the 38 kDa protein as HuR (predicted mo-
lecular mass 36 kDa).
Fig. 1. HuR forms a cAMP-dependent complex with the SGLT1
URE sequence. Gel mobility supershift analysis was carried out by
incubating extracts from control or IBMX-treated cells with the in-
dicated sense RNA transcripts. After digestion of unprotected
RNA, RNA/protein complexes were incubated with either a mono-
clonal antibody (MAb) to HuR (+) or a control, non-speci¢c mono-
clonal antibody (3) before electrophoresis on non-denaturing poly-
acrylamide gels. A: Nuclear (15 Wg protein) or cytoplasmic (40 Wg
protein) extracts were incubated with either the wild-type 120 nt
RNA transcript or the mutant 120 nt transcript (120 nt m2). B: Cy-
toplasmic extracts (40 Wg protein) were incubated with the 47 nt
transcript.
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We also tested antibodies to other proteins which bind
stability-regulating sequences. hnRNPA1 forms a complex
with HuR at a stability-regulating site in L-adrenergic receptor
mRNA [25]. hnRNPD (AUF1), binds the c-fos AU-rich
stability element (ARE) [27]. Monoclonal antibodies to
hnRNPA1 and AUF1 each failed to supershift complexes
formed with the 120 nt SGLT1 URE riboprobe in extracts
from LLC-PK1 cells. However these antibodies did supershift
complexes formed with the 207 nt c-fos ARE transcript using
the same extracts (data not shown). Heat shock proteins have
been shown to bind RNA motifs involved in stability regula-
tion [28]. Antibodies to heat shock proteins hsp70 and hsp90
failed to supershift proteins bound to the 120 nt SGLT1 URE
riboprobe but did supershift proteins bound to the c-fos ARE
riboprobe tested using the same extracts (data not shown).
3.2. HuR binding is protein phosphorylation-dependent
Results shown in Fig. 2 indicate that phosphatase treatment
of nuclear extracts from IBMX-treated cells greatly dimin-
ished the supershifted HuR complex and also reduced forma-
tion of all complexes. A phosphorylation-dependence of the
HuR supershifted complex was also observed using the 47 nt
transcript (data not shown). These ¢ndings indicate that asso-
ciation of HuR and other proteins with the stability-regulating
domain of SGLT1 mRNA is dependent on phosphorylation
of protein(s) within the cell extracts.
3.3. Binding of expressed recombinant HuR
We next tested whether transiently expressed recombinant
HuR recognized the SGLT1 stability-regulating sequence
(Fig. 3). Since protein binding to the SGLT1 URE is
cAMP- and phosphorylation-dependent, we tested recombi-
nant HuR expressed in IBMX-treated LLC-PK1 cells rather
than the puri¢ed GST^HuR fusion protein. An epitope tag
was used to distinguish recombinant HuR from endogenous
HuR. Myc-tagged HuR expressed from plasmid pTet-Myc-
over-HuR has previously been shown to bind the c-fos ARE
[18]. LLC-PK1 clone B7 cultures stably expressing the tetra-
cycline-regulated transactivator [11] were transiently trans-
fected with pTet-Myc-over-HuR in the presence of tetracy-
cline. After 15 h, DNA and tetracycline were removed to
permit expression from the plasmid and cultures were main-
tained an additional 48 h in the presence or absence of 1 mM
IBMX.
Nuclear extracts from transfected cells were assayed by gel
mobility shift using the 32P-labeled 120 nt SGLT1 URE probe
and a monoclonal antibody to the myc epitope tag. Fig. 3A
demonstrates that a di¡use supershifted complex, denoted by
the bracket, was observed in nuclear extracts from IBMX-
treated cells transfected with pTet-Myc-over-HuR after incu-
bation of the binding mixture with the anti-myc tag antibody.
This band was not observed in the absence of IBMX treat-
ment, or in samples incubated with the control monoclonal
antibody, nor was it observed in nuclear extracts from cul-
tures transfected with the empty vector. The di¡usiveness of
the supershifted band may be due to proteolysis of the myc
epitope tag in cell extracts despite the presence of protease
inhibitors.
Nuclear extracts from transiently transfected cells were also
assayed by UV crosslinking. Formation of the single 50 kDa
RNA/protein crosslinked complex with the 47 nt transcript
was greatly increased in nuclear extracts from IBMX-treated
cultures transiently expressing recombinant myc-HuR com-
Fig. 2. HuR binding is decreased after phosphatase treatment. Nu-
clear (15 Wg protein) extracts from IBMX-treated cells were incu-
bated for 30 min at 37‡C with 52 units/mg protein of potato acid
phosphatase in 20 mM MOPS, pH 5.8 and 5 mg/ml bovine serum
albumin. Then, aliquots were diluted into binding assay mixtures at
pH 7.6 and incubated for 15 min with the 32P-labeled 120 nt
SGLT1 probe, digested with ¢ve units of ribonuclease T1 for 30
min followed by 30 min incubation with the indicated monoclonal
antibody (MAb). (+) A monoclonal antibody to HuR; (3) control,
non-speci¢c monoclonal antibody. Samples were immediately ana-
lyzed on non-denaturing 6% polyacrylamide gels.
Fig. 3. Ectopic expression of myc-tagged recombinant HuR. LLC-
PK1 cells stably expressing the tetracycline-regulated transactivator
[11] were transiently transfected with plasmid pTet-Myc-over-HuR
(HuR) or the empty vector (vector). Nuclear extracts were prepared
from control or IBMX-treated cells at 48 h after transfection. A:
Gel mobility supershift analysis was carried out by incubating ex-
tracts (15 Wg protein) with the 32P-labeled 120 nt SGLT1 URE
RNA probe, followed by digestion of unprotected RNA and incu-
bation with either a monoclonal antibody (MAb) to the myc tag
epitope (+) or a control, non-speci¢c monoclonal antibody (3). The
supershifted band is indicated by the bracket. B: Extracts (20 Wg)
were also assayed by UV crosslinking using the 47 nt SGLT1 URE
probe. C: Western blot analysis of nuclear extracts (15 Wg protein)
from transfected cells using the anti-myc tag antibody.
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pared with the endogenous binding activity assessed using
vector controls and compared with myc-HuR-transfected cul-
tures not treated with IBMX (Fig. 3B). These results indicate
that expressed recombinant HuR formed a crosslinked RNA/
protein complex co-migrating with that formed by the endog-
enous RNA binding activity, identi¢ed by gel mobility shift
experiments (shown in Fig. 1) as HuR. Both endogenous and
recombinant RNA binding activities are activated after cAMP
elevation.
Western blot analysis using the anti-myc tag antibody dem-
onstrated increased levels of a 45 kDa protein in nuclear ex-
tracts from myc-HuR-transfected cells compared with vector
controls (Fig. 3C). This size is in agreement with that previ-
ously determined for myc-tagged HuR expressed from this
vector [18] and con¢rms expression of this recombinant pro-
tein. Background staining of a slower-migrating band ob-
served in cultures transfected with the empty vector was
also noted. Expressed levels of immunodetectable protein
were not appreciably in£uenced by IBMX treatment. There-
fore increased RNA/protein complex formation after IBMX
treatment of myc-HuR-expressing cells re£ects cAMP-depen-
dent activation of the RNA binding activity of myc-HuR
rather than increased levels of the protein.
4. Discussion
The transition from an actively dividing, undi¡erentiated
cell population to a functionally and morphologically di¡er-
entiated renal epithelial cell monolayer is accompanied by an
8-fold increase in half-life of SGLT1 mRNA mediated by a
URE in its 3P UTR [10^12,29]. We have utilized gel mobility
supershift analysis to identify HuR as one of the nucleocyto-
plasmic proteins which interacts with the SGLT1 URE.
Our results provide the ¢rst demonstration that HuR bind-
ing to its cognate site in the 3P UTR of an mRNA is stimu-
lated after intracellular cAMP elevation and is dependent on
phosphorylation of protein(s) in the cell extract. Importantly,
a cis-acting substitution mutation within a critical uridine
pentamer in the URE which prevented cAMP-dependent sta-
bilization of a chimeric reporter message also prevented HuR
binding. This observation indicates that cAMP-dependent
binding of HuR is critical for cAMP-dependent SGLT1 mes-
sage stabilization.
HuR was initially shown to bind AREs in the 3P UTRs of
proto-oncogene, growth factor, cytokine and lymphokine
mRNAs [30]. Subsequently, the list of its target mRNAs has
been expanded to include the L-adrenergic receptor mRNA
[25], cyclin mRNAs [20], the cyclin kinase inhibitor p21
mRNA [21], plasminogen activator inhibitor mRNA [31]
and nitric oxide synthase mRNA [23]. The presence of a bind-
ing site for HuR in the 3P UTRs of diverse mRNAs suggests
that their decay rates can be co-ordinately regulated in re-
sponse to cell signaling pathways.
The direct involvement of HuR in message stabilization was
demonstrated using antisense constructs [20,22,23], a cell-free
mRNA decay system [32] and by ectopic overexpression
[18,19,22,23,33]. Stabilizing e¡ects of HuR overexpression
could not be tested in LLC-PK1 cells, since cAMP elevation
resulted in maximal stabilization of reporter transcripts bear-
ing the SGLT1 URE, with over 90% of transcripts remaining
at 10 h after inhibition of transcription [12].
A key property of HuR is its ability to shuttle between the
nucleus and cytoplasm [19,34]. HuR may bind its target
mRNAs in the nucleus and accompany them to the cyto-
plasm, providing protection from degradation. The recent
identi¢cation of a novel, speci¢c endonuclease that cleaves
within a HuR binding site and is speci¢cally inhibited by
HuR [35] suggests that HuR may bind near an endonuclease
recognition site in order to render it inaccessible to endonu-
clease action.
The interaction between HuR and its target mRNAs was
regulated by three proteins known to be protein phosphatase
2A inhibitors [36]. These ¢ndings, taken together with our
demonstration that HuR binding to the SGLT1 URE is
inhibited by dephosphorylation of cellular protein(s) and
increased after cAMP elevation, point to a key role for a
regulatory cascade and protein phosphorylation/dephos-
phorylation in RNA stabilization by HuR.
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